The "Psychiatry Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025. Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of the report provide an introduction and trend analysis in psychiatry dealmaking, followed by a detailed examination of financial deal terms, including headline value, upfront payment, milestone payment, and royalty rates. It also reviews the activities of the top 25 biopharma companies involved in psychiatry deals and provides insights through available contract documents. A comprehensive directory is included, listing psychiatry deals by therapeutic target, alongside several tables and figures illustrating trends since 2019.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

2.1. Introduction

2.2. Psychiatry partnering over the years

2.3. Psychiatry partnering by deal type

2.4. Psychiatry partnering by industry sector

2.5. Psychiatry partnering by stage of development

2.6. Psychiatry partnering by technology type

2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

3.1. Introduction

3.2. Disclosed financials terms for psychiatry partnering

3.3. Psychiatry partnering headline values

3.4. Psychiatry deal upfront payments

3.5. Psychiatry deal milestone payments

3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

4.1. Introduction

4.2. Most active in psychiatry partnering

4.3. List of most active dealmakers in psychiatry

4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

5.1. Introduction

5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by psychiatry therapeutic target

Deal directory

• Deal directory - Psychiatry deals by company A-Z 2019 to 2025
• Deal directory - Psychiatry deals by technology type 2019 to 2025
• Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/t428nv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250721272089/en/